Literature DB >> 11091144

Trends over time in the incidence of cervical neoplasia in comparison to trends over time in human papillomavirus infection.

J Dillner1.   

Abstract

INTRODUCTION: The establishment of human papillomavirus (HPV) infection as a major cause of cervical neoplasia has resulted in major efforts to develop prophylactic HPV vaccines for prevention of cervical neoplasia. Cervical cancer and the other HPV-associated cancers constitute a major public health burden and eradication of the major causative infection is certainly the most appealing long-term preventive measure. Nevertheless, the effects of preventive HPV vaccination will need to be estimated and compared for (cost-) efficacy with other primary prevention and with secondary prevention programs. However, estimating the effects of preventing a causative exposure is complicated when the exposure is a transmissible infection. The spread of the epidemic is dynamic and may change over time depending e.g. on the changes in human behavior. Depending on the circumstances, prevention of an infection may have either greater or lesser effects than the prevention of a non-infectious exposure. Estimating the time trends in HPV infections and the underlying trends in the risk of cervical neoplasia is important for estimating effects of interventions.
METHOD: A literature review on recent evidence on time trends in cervical neoplasia, compared with evidences on time trends in HPV infections and interactions between different types of HPV infections.
RESULTS: In Finland, there has between 1991 and 1995 been a 60% increase in the incidence of cervical cancer among women <55 years of age. Trends in detection rates of cervical cancer precursor lesions are consistent with an increase in the background cervical cancer risk. From the 1960s to 1980s, there has been a major increase in HPV seroprevalences over time in the Nordic countries. Increasing trends are also seen for other sexually transmitted diseases and smoking. Several studies indicate the existence of interaction between benign and oncogenic HPV types, thus making the relationship between the incidences in HPV infections and in cervical neoplasia complex.
CONCLUSION: The increase in cervical cancer is paralleled by increases in HPV infection, other STDs and smoking and changes in screening practices, all of which may have contributed. Prediction of the effect on cervical cancer incidence of changes in HPV incidences is complicated by the existence of several risk factors, the protective effect of screening and by the population dynamics of HPV infections.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11091144     DOI: 10.1016/s1386-6532(00)00126-8

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  6 in total

1.  Outcomes of screening to prevent cancer: analysis of cumulative incidence of cervical abnormality and modelling of cases and deaths prevented.

Authors:  A E Raffle; B Alden; M Quinn; P J Babb; M T Brett
Journal:  BMJ       Date:  2003-04-26

2.  Seroprevalences of herpes simplex virus type 2, five oncogenic human papillomaviruses, and Chlamydia trachomatis in Katowice, Poland.

Authors:  Staffan Görander; Teresa Lagergård; Malgorzata Romanik; Raphael P Viscidi; Gayane Martirosian; Jan-Ake Liljeqvist
Journal:  Clin Vaccine Immunol       Date:  2008-02-20

3.  Vaginal Infections of Albanian women Infected with HPV and their impact in intraepithelial cervical lesions evidenced by Pap test.

Authors:  Elsa S Kone; Avenir D Balili; Piro D Paparisto; Xheladin R Ceka; Elizana D Petrela
Journal:  J Cytol       Date:  2017 Jan-Mar       Impact factor: 1.000

4.  Changes in antibody seroprevalence of seven high-risk HPV types between nationwide surveillance studies from 1995-96 and 2006-07 in The Netherlands.

Authors:  Mirte Scherpenisse; Madelief Mollers; Rutger M Schepp; Hein J Boot; Chris J L M Meijer; Guy A M Berbers; Fiona R M van der Klis; Hester E de Melker
Journal:  PLoS One       Date:  2012-11-12       Impact factor: 3.240

5.  50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence.

Authors:  S Vaccarella; S Franceschi; G Engholm; S Lönnberg; S Khan; F Bray
Journal:  Br J Cancer       Date:  2014-07-03       Impact factor: 7.640

6.  Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine.

Authors:  Karl-Ulrich Petry; Kaatje Bollaerts; Paolo Bonanni; Margaret Stanley; Rosybel Drury; Elmar Joura; Susanne K Kjaer; Chris J L M Meijer; Didier Riethmuller; Benoit Soubeyrand; Pierre Van Damme; Xavier Bosch
Journal:  Hum Vaccin Immunother       Date:  2018-05-24       Impact factor: 3.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.